Nicholas Farrell is an Oncology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9707 Medical Center Dr
Suite 300
Rockville, MD 208503348
Telephone
301-424-6231Registry record last updated 5 May 2009.
Industry payments
31 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20258 payments
- GlaxoSmithKline, LLC.Program year20255 payments
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48.9%Nucleoside Metabolic Inhibitor16.6%Azacitidine98%Fluorouracil2%Part B, office-administered≥17 patientsCD38-directed Cytolytic Antibody10.8%Daratumumab100%Part B, office-administered≥16 patients+ 10 more classes in this area
Blood & clotting
36.2%Erythropoiesis-stimulating Agent20.3%Darbepoetin alfa100%Part B, office-administered≥34 patientsIron, parenteral preparations15.7%Ferric carboxymaltose84%Ferric derisomaltose16%Part B, office-administered≥23 patients+ 3 more classes in this area
Metabolism & gastrointestinal
7%Substance P/Neurokinin-1 Receptor Antagonist5.6%Aprepitant100%Part B, office-administered≥25 patientsSerotonin-3 Receptor Antagonist1.3%Palonosetron hcl65%Granisetron hydrochloride35%Part B, office-administered≥39 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”